At low magnification (×40), there is an acanthotic and mildly spongotic epidermis with minimal interface, eosinophils in the dermis, and overlying parakeratosis (hematoxylin-eosin).

pathogenesis and relationship to the associated malignant condition are not well understood. Theories include tumor antigens cross-reacting with antigens of the skin BMZ, a cellular immune response with cytotoxic effects, tumor growth factors inducing hyperkeratosis (transforming growth factor α, epidermal growth factor, or insulin-like growth factor 1), or zinc and vitamin A deficiency from tumor expansion.5,6

The eruption is generally symmetric and nonpruritic, with violaceous to pink patches and plaques with hyperkeratosis of acral sites.3–5 The extremities and trunk can be involved.3–6 The palms and soles may have hyperkeratosis and fissures, as in keratoderma.5 Nail changes are frequently seen, including onycholyosis and subungual debris.4 Edema of the distal extremities and vesicular formation is infrequently seen.3,5,7

The cutaneous manifestations present, on average, 11 months prior to the discovery of cancer, but in 20% of the cases, the malignant neoplasm is diagnosed at the time of the skin eruption.3,5 Squamous cell carcinoma is the most commonly associated malignant condition.5 Other cancers include poorly differentiated carcinoma, adenocarcinoma, small cell carcinoma, lymphoma, and cholangiocarcinoma. The majority of associated malignant neoplasms occur above the diaphragm and involve the upper one-third of the aerodigestive tract.

Bazex syndrome may resemble more common diseases such as psoriasis. Therefore, a biopsy is generally helpful, though the findings are typically nonspecific. Common reported findings include hyperkeratosis, acanthosis, parakeratosis, dyskeratotic keratinocytes, and perivascular infiltrates.4–5 Immunofluorescence has been performed in a minority of cases, and its results are generally nonspecific.5 Our patient’s clinical findings were concerning for a blistering disease, but neither hematoxylin-eosin nor direct immunofluorescence evaluation showed evidence of bullous pemphigoid or paraneoplastic pemphigus.

Symptomatic improvement can be achieved by treating the underlying malignant condition; return of skin lesions can signify tumor recurrence.5 While skin-directed therapy might be helpful to control symptoms, the responses are variable and suboptimal.

In summary, we present herein a case of acrokeratosis paraneoplastica with rapid onset of cutaneous findings and the development of many vesicles and bullae. Furthermore, we demonstrate the diagnostic role of biopsy and immunofluorescence testing in this patient.

Stephen R. Humphrey, MD
Amara S. Hussain, MD
Rekha Chandran, MD
Barbara Wilson, MD
Ben George, MD

**Author Affiliations:** Department of Dermatology, Medical College of Wisconsin, Milwaukee (Humphrey, Hussain); Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin (Chandran, Wilson); Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (Chandran, George).

**Corresponding Author:** Stephen R. Humphrey, MD, Department of Dermatology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226 (shumphre@mcw.edu).

**Published Online:** March 11, 2015. doi:10.1001/jamadermatol.2014.5622.

**Conflict of Interest Disclosures:** Dr George serves as a consultant to Celgene and Cook Medical. No other disclosures are reported.

**Correction:** This article was corrected on March 25, 2015, to add the middle initial to the name of author Amara S. Hussain, MD.


**Erythrodermic Epidermolysis Bullosa Acquisita**

Epidermolysis bullosa acquisita (EBA) is a rare acquired subepidermal blistering autoimmune disease of the skin and mucosae associated with autoantibodies directed against type VII collagen, the major component of the anchoring fibrils of the dermal-epidermal junction.1,2 Various clinical presentations of EBA have been described, including a noninflammatory mechnobullous form, an inflammatory bullous pemphigoid (BP)-like form, and a mucous-membrane pemphigoid-like form. These forms may show clinical overlap, and their courses are often unpredictable.1,3

**Report of a Case** | A 60-year-old man was admitted for evaluation of a 3-week history of widespread pruritic cutaneous lesions. The patient had taken no drugs, and his medical history was unre-
markable. On examination, almost his entire trunk, buttocks, and thighs were erythematous and infiltrated with papular and urticarial lesions (Figure 1). Islands of normal-appearing skin were observed. On his soles and palms, isolated lesions with a target-like appearance were noted. The head as well as the oral and genital mucous membranes were spared. During hospital admission, the patient developed isolated vesicles and serous blisters on erythematous skin on his wrist and ankle.

Light microscopy studies of a skin biopsy specimen obtained from patient’s back showed a diffuse spongiosis with a mixed perivascular inflammatory infiltrate consisting of eosinophils and neutrophils in the upper dermis (Figure 2). Direct immunofluorescence microscopy studies disclosed linear deposits of IgG and C3 along the epidermal basement membrane zone. By indirect immunofluorescence microscopy using sodium chloride-separated normal human skin, circulating IgG autoantibodies binding the dermal side of the split were detected.

Immunoblotting analysis using human dermal extracts showed a reactivity with a 290-kDa protein showing the same electrophoretic migration to the protein band recognized by the control monoclonal antibody directed against type VII collagen.

Based on the clinical features and immunopathological findings, the diagnosis of EBA was made. The patient was given oral prednisolone, 0.75 mg/kg of body weight, which resulted in rapid clearance of the lesions within 2 weeks. Corticosteroid doses were subsequently slowly tapered. At a dose of 10 mg/d, the patient experienced a relapse and began treatment with methotrexate, 15 mg subcutaneously once weekly. The prednisolone dose was then tapered to 2.5 mg/d, and the patient remained asymptomatic at 6-month follow-up.

Discussion | The clinical features of EBA are protean. The classic presentation is that of a noninflammatory mechanobulbous disease characterized by the development of acral blisters that heal with atrophic scarring, milia, and hyperpigmentation or hypopigmentation. They are localized to trauma-prone surfaces such as elbows, knees, hands, and feet. Acral involvement may be mutilating. Scalp involvement occurs in up to 20% of patients. The inflammatory BP-like presentation is associated with widespread vesicles and bullae involving intertriginous and flexural areas that heal without atrophic scarring. Epidermolysis bullosa acquisita may also present as mucous membrane pemphigoid or as Brunsting-Perry pemphigoid phenotype. The potential causes of erythroderma include psoriasis, atopic dermatitis, drug reactions, and cutaneous T-cell lymphoma. With the exception of pemphigus foliaceus, the other autoimmune bullous diseases of the skin have been only anecdotally implicated as cause of erythroderma. Specifically, single cases of erythrodermic BP have been described. Epidermolysis bullosa acquisita is potentially associated with a number of systemic diseases, including inflammatory bowel diseases, but our patient showed no evidence of any of these.
Our case was striking because the patient initially showed features suggestive of either a severe drug reaction or a paraviral eruption, but immunopathological studies were diagnostic for EBA. Our observation provides a further example about the polymorphous and misleading presentations of EBA. Hence, EBA should be considered as a rare cause of erythroderma.

Stefanie Häfliger, MD
Hans-Wilhelm Klötgen, MD
Michael Horn, PhD
Helmut Beltraminelli, MD
Luca Borradori, MD

Author Affiliations: Department of Dermatology, University of Berne, Inselspital, Berne, Switzerland (Häfliger, Klötgen, Beltraminelli, Borradori); Department of Immunology, University of Berne, Inselspital, Berne, Switzerland (Horn).

Corresponding Author: Stefanie Häfliger, MD, Universitätsklinik für Dermatologie, Inselspital, 3010 Bern, Schweiz (stefanie.haefliger@insel.ch).


Conflict of Interest Disclosures: None reported.

Additional Contributions: The authors are indebted to Lionel Fontao, PhD, Department of Dermatology, University of Geneva, for performing the search of anti-type VII collagen antibodies by immunoblotting studies.